Biosimilars: Are They Delivering the Cost Savings Promised?

Since the first FDA biosimilar approval of filgrastim-sndz (Zarxio) in 2015, a total of 44 biosimilars for 15 originator products have been approved and more than 20 are marketed.

Related Keywords

United States ,Colorado ,Maryland ,American ,Megan Holsopple ,Neulasta Onpro ,Vizient Biosimilar ,Client Programs At Arrive Health ,Drug Administration ,American Diabetes Association ,Academy Of Managed Care Pharmacy ,Partnership Forum ,Arrive Health ,Real Time Prescription Benefit ,Prescribing Practices ,Real Time Prescription ,Cost Considerations ,Are Biosimilars ,Vice President ,Client Programs ,Accessed December ,Purple Book ,Licensed Biological ,Managed Care Pharmacy ,Manag Care Spec Pharm ,Manag Care Spec ,